Figure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

2026 Open access

Read full text
Authors: Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas, Daniel Korr, Haruna Tomono, Sawyer Andersen, D.R. Denney, Markus Berger, Volker Schulze, Timothy A. Lewis, Bethany Kaplan
+14 more Sven Golfier, Jérémie Mortier, Roman Christian Hillig, Ulf Boemer, Kirstin Petersen, Knut Eis, Sybil M. Genther Williams, Dominik Rüttinger, Andrew D. Cherniack, Herbert Ho-Fung Loong, Koichi Goto, Paolo Grassi, Matthew M. Meyerson, Heidi E. Greulich
DOI: 10.1158/2159-8290.31047106
Cited by: 0

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Lung Cancer Research Studies

Publication details

Publication date
12 January 2026